The majority of patients (> 80%) had stage I or II breast cancer, 62.6% were estrogen receptor-positive, and 90.2% had received prior anthracycline-based chemotherapy before starting H IV treatment (Table 1). The gene discussed is ESR1; the disease is breast carcinoma.